Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Nurix Therapeutics Enters License and Collaboration Agreement with Roche
Jun 08, 2026
Contract Type
licensing
San FranciscoOtherBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma
Description
On June 6, 2026, Nurix Therapeutics, Inc. signed a License and Collaboration Agreement with F. Hoffmann-La Roche Ltd. and Genentech, Inc
Company Information
Company
Nurix Therapeutics
Location
San Francisco, California, United States
About
Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases. The company is focused on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases.